Liminal BioSciences Inc logo

LMNL - Liminal BioSciences Inc Share Price

C$22.84 -0.5  -2.1%

Last Trade - 05/08/20

Sector
Healthcare
Size
Small Cap
Market Cap £308.9m
Enterprise Value £309.6m
Revenue £410k
Position in Universe 321st / 2679
Bullish
Bearish
Unlock LMNL Revenue
Momentum
Relative Strength (%)
1m +6.36%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -29.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
23.0 24.5 16.4 39.1 24.6 4.90 5.71 13.6 -26.6%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the three months ended 31 March 2020, Liminal BioSciences Inc revenues decreased 51% to C$1.1M. Net loss before extraordinary items decreased 4% to C$27.3M. Revenues reflect Plasma derived therapeutics segment decrease of 59% to C$901K, Small mole Cule segment decrease from C$31K to C$0K, United States segment decrease of 49% to C$731K, Canada segment decrease of 76% to C$205K.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

LMNL Revenue Unlock LMNL Revenue

Net Income

LMNL Net Income Unlock LMNL Revenue

Normalised EPS

LMNL Normalised EPS Unlock LMNL Revenue

PE Ratio Range

LMNL PE Ratio Range Unlock LMNL Revenue

Dividend Yield Range

LMNL Dividend Yield Range Unlock LMNL Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
LMNL EPS Forecasts Unlock LMNL Revenue
Profile Summary

Liminal BioSciences Inc., formerly Prometic Life Sciences Inc., is a Canada-based biopharmaceutical company. The Company is focused on developing a pipeline of small molecule therapeutics to treat patients with liver, respiratory and kidney disease, with a focus on rare or orphan diseases. It operates through three segments: Small Molecule Therapeutics Segment, Plasma-derived Therapeutics Segment and Bioseparations segment. The Small Molecule Therapeutics Segment is a small-molecule drug development business. The Plasma-derived Therapeutics Segment includes its plasma-derived therapeutics platform, which enables the development of its pipeline of biopharmaceutical candidates. Bioseparations segment is engaged in bioseparation, specifically for purification of biologics and the elimination of pathogens. Its product candidates include PBI-4050, PBI-4547, Ryplazim IV and Inter Alpha Inhibitor Protein (IAIP).

Directors
Last Annual December 31st, 2019
Last Interim March 31st, 2020
Incorporated October 14, 1994
Public Since October 14, 1994
No. of Shareholders: n/a
No. of Employees: 300
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange Toronto Stock Exchange
Shares in Issue 23,622,660
Free Float (0.0%)
Eligible for
ISAs
SIPPs
LMNL Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for LMNL
Upcoming Events for LMNL
Frequently Asked Questions for Liminal BioSciences Inc
What is the Liminal BioSciences Inc share price?

As of 05/08/20, shares in Liminal BioSciences Inc are trading at C$22.84, giving the company a market capitalisation of £308.9m. This share price information is delayed by 15 minutes.

How has the Liminal BioSciences Inc share price performed this year?

Shares in Liminal BioSciences Inc are currently trading at C$22.84 and the price has moved by 52.32% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Liminal BioSciences Inc price has moved by 50.13% over the past year.

What are the analyst and broker recommendations for Liminal BioSciences Inc?

Of the analysts with advisory recommendations for Liminal BioSciences Inc, there are there are currently 0 "buy" , 2 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Liminal BioSciences Inc is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Liminal BioSciences Inc next release its financial results?

Liminal BioSciences Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-03-31
What is the Liminal BioSciences Inc dividend yield?

Liminal BioSciences Inc does not currently pay a dividend.

Does Liminal BioSciences Inc pay a dividend?

Liminal BioSciences Inc does not currently pay a dividend.

When does Liminal BioSciences Inc next pay dividends?

Liminal BioSciences Inc does not currently pay a dividend.

How do I buy Liminal BioSciences Inc shares?

To buy shares in Liminal BioSciences Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Liminal BioSciences Inc?

Shares in Liminal BioSciences Inc are currently trading at C$22.84, giving the company a market capitalisation of £308.9m.

Where are Liminal BioSciences Inc shares listed? Where are Liminal BioSciences Inc shares listed?

Here are the trading details for Liminal BioSciences Inc:

Country of listing: Canada
Exchange: TOR
Ticker Symbol: LMNL
What kind of share is Liminal BioSciences Inc?

Based on an overall assessment of its quality, value and momentum, Liminal BioSciences Inc is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Liminal BioSciences Inc share price forecast 2020?

Shares in Liminal BioSciences Inc are currently priced at C$22.84. At that level they are trading at 8.06% premium to the analyst consensus target price of 0.00.

Analysts covering Liminal BioSciences Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.07 for the next financial year.

How can I tell whether the Liminal BioSciences Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Liminal BioSciences Inc. Over the past six months, the relative strength of its shares against the market has been 84.84%. At the current price of C$22.84, shares in Liminal BioSciences Inc are trading at 93.26% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Liminal BioSciences Inc PE Ratio?

We were not able to find PE ratio data for Liminal BioSciences Inc.

Who are the key directors of Liminal BioSciences Inc?

Liminal BioSciences Inc's management team is headed by:

Bruce Pritchard - COO
Patrick Sartore - COO
John Moran - OTH
Charles Kenworthy - DRC
Stefan Clulow - CHM
Simon Best - LED
Kenneth Galbraith - CEO
Zachary Newton - DRC
Gary Bridger - IND
Neil Klompas - IND
Timothy Wach - IND
Moira Daniels - OTH
Marie Iskra - GCN
Martin Leclerc - CHO
Murielle Lortie - CFO
Who are the major shareholders of Liminal BioSciences Inc?

Here are the top five shareholders of Liminal BioSciences Inc based on the size of their shareholding:

Structured Alpha, L.P. Corporation
Percentage owned: 70.77% (16.7m shares)
Consonance Capital Management LP Hedge Fund
Percentage owned: 13.92% (3.29m shares)
Morgan Stanley Canada Limited Research Firm
Percentage owned: 0.15% (34.4k shares)
Pengana Capital Group Limited Investment Advisor/Hedge Fund
Percentage owned: 0.06% (14.1k shares)
Pengana High Conviction Equities Fund Mutual Fund
Percentage owned: 0.06% (14.1k shares)
Similar to LMNL
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.